These results shed light on the mechanism of SALL2‐mediated ERα regulation in a subset of breast cancers and highlight a clinical biosignature that could be used to identify breast cancer patients who might benefit from co‐therapy with tamoxifen and DNMT inhibitor. Here, SALL2 is linked to breast carcinoma.